Treatment patterns and outcomes in elderly patients with multiple myeloma
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Age at diagnosis is an important determinant of outcome among patients with multiple myeloma (MM). The median age at diagnosis is 70 years in the United States, which is similar to that in the United Kingdom (73 years) and Sweden (70 years). [1] [2] [3] The subgroup over the age of 75 years represents a population in which the natural history of the disease and outcomes are not well studied. [4] [5] [6] [7] In one report, the median survival was less than 6 Letters to the Editor months in patients greater than 75 years of age, and hemoglobin and age were significant predictors of survival. 4 Rodon et al. 6 reported a median survival of 22 months in patients 475 years of age. Poor performance and elevated creatinine were adverse prognostic factors in this study. However, the majority of patients received melphalan or cyclophosphamide with prednisone and represent the era before introduction of the novel agents. The IFM01/01 trial 8 enrolled patients over 75 years and showed a prolongation of survival with modest toxicity with melphalan, prednisone and thalidomide. We performed the current study to better define the outcome among patients over 75 years, who were seen at the Mayo Clinic between 1 January 1999 and 31 December 2008. The treatment responses were estimated according to the Uniform Response Criteria of the International Myeloma Working Group. 9 The survival of MM patients aged p75 years in the same period was also reviewed for comparison. The study was approved by the Institutional Review Board.
Two hundred and twelve patients 475 years of age with symptomatic MM were diagnosed during the study period. Among them, 73 patients (34%) with inadequate follow-up were excluded and the remaining 139 patients (66%) constitute the current study. Their median age was 80 years (range: 76-94) and 57% were male. During the same 10-year period, 1290 patients aged p75 years were seen. Their median age was 62 years (range: 23-75) and 79 (54%) were male. Among the 139 study patients, 20 (14%) patients were over 85 years of age. A decreased performance score (X2) was observed in 44 patients (32%). Among 90 tested patients, 30 (33%) had cytogenetic abnormalities with 13% classified as high risk, because of monosomy 13 or hypodiploidy in conventional G-banding. Twenty-seven of 31 patients with fluorescent in situ hybridization (FISH) had abnormal results. We detected 7 patients (26%) with t(4;14), t(14;16) or deletion 17p among 27 patients with abnormal FISH results. Non-plasma cell malignancies were diagnosed in 45 patients including 33 with solid tumors and 12 with hematologic malignancies. Three patients developed myelodysplastic syndrome following their diagnosis of myeloma. Fourteen (10%) patients also had concomitant AL (Amyloid composed of immunoglobin Light chains) amyloidosis involving the heart, kidney, gastrointestinal tract or soft tissue. Seven patients had plasmacytoma. One hundred and twenty-two patients were treated at Mayo Clinic; 17 patients were not treated because of their poor condition or co-morbidities (n ¼ 15) and patients' refusal of therapy (n ¼ 2). Front-line therapy consisted of conventional agents in 87 (71%) patients; melphalan and prednisone (MP) or dexamethasone in 82 (67%) patients, dexamethasone alone in 4 and a combination of alkylating agents in 1 patient. Among them, 34 (39%) patients received novel The regimens with novel agents were lenalidomide and dexamethasone (n ¼ 8), thalidomide and dexamethasone (n ¼ 8), MP with lenalidomide (n ¼ 6), cyclophosphamide, lenalidomide and dexamethasone (n ¼ 6) and MP with thalidomide (n ¼ 4) and velcade-containing regimens (n ¼ 3). Otherwise, conventional therapy included melphalan with prednisone (MP) or dexamethasone (n ¼ 82), dexamethasone (n ¼ 4) and VBMCP (n ¼ 1).
f Response was assessed using criteria of the International Myeloma Working Group. Bold values are statistically significant at Po0.005. agents for progressive or recurrent disease during the disease course. Novel agents were given to 35 (29%) patients as front-line therapy; lenalidomide and dexamethasone in 8, thalidomide and dexamethasone in 8; melphalan, prednisone and lenalidomide in 6; lenalidomide, cyclophosphamide and dexamethasone in 6; melphalan, prednisone and thalidomide in 4; and bortezomibcontaining regimens in 3. Novel agents as the first-line therapy accounted for over half of the regimens since 2006. The number of patients who received novel agents at any time was 69 (50%). Response to the first therapy was observed in 59 (48%) patients among 122 treated patients. The response rate was 45% in patients with conventional therapy and 57% with novel agents. Complete response (CR) (9%) and near CR was higher (26%) in the 35 patients given novel agents as first-line therapy. Nine patients obtained a CR or near CR, four had a very good partial response (VGPR) and seven had a partial response (PR) from novel agents given as first-line therapy. The response rates are summarized in Figure 1 . The response to front-line therapy was not evaluable in 20 patients with conventional agents and 6 with novel agents because of early discontinuation of therapy from toxicity in 23 patients, transfer to another hospital in 2 patients and family decision in 1 patient. Deaths during the first chemotherapy regimen occurred in 10 patients (8%). Death was due to sepsis in three, pancreatitis in one and unknown in six patients. The median duration of front-line therapy was 9 months (95% confidence interval (CI): 8-11) in 121 patients. The progression-free survival from front-line therapy was 20 months (95% CI: 17-24). The median number of regimens was 2 (range: 1-8). Twenty patients are still receiving treatment and 6 patients are still on the first regimen. The median survival of all 212 patients and the 139 patients who were managed at Mayo Clinic were 24 months (95% CI: 18-30) and 27 months (95% CI: 20-35), respectively. These are significantly less than the 62 months (95% CI: 56-68) in patients p75 years old (Po0.001) seen during the same time. The median survival of 122 patients receiving therapy was 30 months (95% CI: 12-39) compared with 2 months (95% CI: 0-4) for the 17 patients declining the treatment. Age 485 years, poor performance status (ECOG (Eastern Cooperative Oncology Group) X2), thrombocytopenia (platelet o150 000/ml) and elevated serum lactate dehydrogenase or b2-microglobulin at diagnosis were significant factors for decreased survival on univariate analysis. Institution of active chemotherapy (versus supportive care only), incorporation of new agents in front-line therapy or at anytime, and achievement of any response were also significant on univariate analysis. Multivariate analysis showed that only poor performance status shortened the survival (Table 1) .
We focused on the comparison of survival before and after the introduction of novel agents in elderly myeloma patients. Thirtyfive patients who received novel agents as first-line therapy as well as 69 patients who received one or more novel agents anytime during the treatment period showed superior survival compared with patients treated with conventional therapy in univariate analysis, but failed to show a survival benefit in multivariate analysis. Salvage therapy with novel agents might explain this result. Patients over 75 years of age who received MP or MP plus thalidomide had a median survival of 44 months compared with 29 months in an IFM (Intergroupe Francophone du Myelome) randomized trial. 8 Our retrospective analysis included elderly patients exposed to various novel agents, and the IFM study also included use of novel agents as rescue treatment in patients with progressive disease. We presume that adequate choice of novel agent according to patients' organ function and modification of dose intensity will prolong the survival of elderly MM patients. The second point is the relation between response to first therapy and survival. Achievement of stabilization or response increased the median survival to 50 months compared with 6 months in patients with progressive or inevaluable disease in our study. The IFM01/ 01study 8 reported higher rates of PR, VGPR and CR in the MP plus thalidomide group, but not an increased survival. They also reported the same overall survival after progression in both the groups. This suggests that appropriate choice of rescue therapy is important in elderly myeloma patients after disease progression. The last comparison is with younger patients in the same period. The significant difference of median survival was observed in our analysis (62 versus 27 months). Elderly patients have more comorbidities such as cardiovascular disease, depression or arthritis. In one report patients aged 65 years or more usually had an average of three different concurrent diseases. 10 Our study contained the 17 untreated patients because of concurrent diseases. They had a short median survival (2 months versus 30 months for treated patients). Elderly MM patients also have limited social and financial support, and reduced functional status, which may interrupt active treatment. Both elderly patients and their physicians are more likely to choose less intensive or supportive therapy, which may be appropriate in patients with significant comorbidities. 11 The reduction of dose and early termination after toxicity are frequent decisions by physician, patient or family during treatment.
It has not been shown that MM has a more malignant biology in elderly patients. Some reports showed aggressive disease in young MM patients.
12-14 Twenty-five percent of our patients had a history of coexistent or subsequent malignancy, which may also shorten the survival. However, there was no significant difference in survival with or without other malignancies (data not shown). AL amyloidosis or plasmacytoma were frequently seen in our elderly MM patients; its frequency was 16.5%. This may result in both reduced organ function and may reflect high tumor burden. In conclusion, myeloma patients over 75 years with a good performance status showed a favorable outcome. They are good candidates for active therapy especially with novel agents. 8 High hyperdiploidy (HeH; 51-67 chromosomes) is seen in B25% of childhood and B7% of adult acute lymphoblastic leukemia (ALL). 1,2 Cases display a massive gain of chromosomes that results in a characteristic pattern of trisomies X, 4, 6, 10, 14, 17, and 18 and tetrasomy 21. In rare instances (2-3% of HeH cases), childhood ALL with a high hyperdiploid chromosome number also harbor t(1;19)(q23;p13)/TCF3-PBX1 fusion, t(9;22)(q34;q11)/ BCR-ABL1 fusion or 11q23/MLL rearrangements (t-HeH). 3 In adult ALL, similar frequencies of HeH and t (1;19) 2 When classifying ALL by genetics, t-HeH cases are usually grouped according to the translocation. Such cases appear to have a worse prognosis than 'classic' HeH (c-HeH) in both children and adults, although this is based on relatively small patient series. 2, 4 It has been reported that patients with t(9;22)-HeH have a better outcome than those with t(9;22) in a diploid context; however, they still display a shorter event-free survival than c-HeH patients. 2, [5] [6] [7] In this study, we have utilized single nucleotide polymorphism (SNP) array analysis to investigate nine t(9;22)-HeH and two MLL-HeH ALL patients (Supplementary Table 1 ). SNP array data from four previously published cases were also included; 8 original case numbers 5, 6, 10 [t(9;22)-HeH] and 11 [t(4;11)(q21;q23)-HeH]. DNA was extracted according to standard methods from bone marrow samples acquired at diagnosis, and SNP array analyses were performed using the Human Omni-1 Quad BeadChip platform (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. Data analyses were done using the GenomeStudio v2011.1 software with Illumina Genome Viewer 1.9.0 (Illumina). In addition, data from ALL cases reported in the literature with 51-67 chromosomes and concurrent (a) t(9;22)(q34;q11), (b) t(4;11)(q21;q23) or t(11;19)(q23;p13), or (c) t(1;19)(q23;p13)/ der(19)t(1;19) were extracted from the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, 3 and data from adult ALL cases with 51-65 chromosomes and one of the above-mentioned rearrangements were extracted from the karyotype database held by the Leukemia Research Cytogenetics Group (LRCG), Newcastle University, UK.
2 Specific gains and modal numbers were ascertained from G-banded karyotypes, as published or reported by clinical laboratories. Cases with a range of modal numbers were classified as having the highest modal number in the range.
The t(9;22)-HeH cases had a median modal number of 55 both by SNP array analysis and in the cytogenetic review, which included 80 t(9;22)-HeH cases from the literature and 44 cases from the LRCG data base, similar to c-HeH (Figure 1a) . 9 In all, 4 (33%) of the 12 cases investigated by SNP array analysis harbored whole-chromosome uniparental isodisomies and 8 of 9 tetrasomies had duplicated both homologs (Supplementary Table 1 ), in line with c-HeH in general. 9 In c-HeH, this pattern has been interpreted as the majority of cases arising in one aberrant mitosis, either directly from diploidy or via a tetraploid state. 10 Taken together, the available data suggest that the HeH in t(9;22)-HeH cases may occur by a similar mechanism. However, case 2, which had a 3:1 tetrasomy 14 indicating sequential gains of that chromosome, and case 9, which had subclonality indicating sequential gains of several chromosomes, may be exceptions. In total, 10% of the t(9;22)-HeH cases in the cytogenetic review and 2/12 cases analyzed by SNP array had a stemline with t(9;22) only. Case 2 displayed the opposite pattern, that is, a stemline with HeH only by G-banding; no such case has been previously reported in the literature. Gain of an extra derivative chromosome 22 was present in 75% of the cases. These findings indicate that the translocation usually arises first, followed by the hyperdiploidy. Another fact that points in the same direction is the pattern of the gains, which displays both similarities and differences compared with the gains in c-HeH. For example, chromosomes X, 4, 6, 14 and 21 were gained in the majority of cases (Figure 2a) , similar to c-HeH. 9 However, trisomies 10, 17 and 18 were much rarer; þ 17 was seen in only 1 (8.3%) of the cases analyzed with SNP array compared with B80% of c-HeH analyzed with the same method (Po0.001; two-tailed Fisher's exact probability test). 9 Trisomy 2, on the other hand, was more frequent, being present in 58% of the t(9;22)-HeH cases compared with 2.7% of c-HeH (Po0.001), and trisomy 19 was seen in 4 (33%) of the 12 cases, but not in a single case of the 74 c-HeH cases previously investigated (Po0.001). 9 This suggests that different chromosomal gains may give a selective advantage in cases that harbor a t(9;22), that is, þ 2 and þ 19 may be leukemogenic in a high hyperdiploid background only if the cell also carries a t(9;22), whereas þ 17 may not.
Few MLL-HeH cases could be evaluated; 3 with SNP array analysis and 11 in the cytogenetic review, of which 10 cases from the literature and 1 from the LRCG database. All cases had modal numbers of 51-53 (Figure 1b; Supplementary Table 1 ), which differs from the pattern seen in c-HeH. 9 This indicates that the underlying mechanism of the gains in MLL-HeH differs from c-HeH. Furthermore, the pattern of chromosomal gains appeared Accepted article preview online 11 September 2012; advance online publication, 2 October 2012
